Impax Laboratories (IPXL) 26.36 $IPXL
Insider Trading Alert - IPXL, ITMN And GMCR Traded By Insiders
at The Street - 53 mins ago
Stocks with insider trader activity include IPXL, ITMN and GMCR
Perrigo Company plc Announces FDA Approval Of Generic Version Of Astepro® Nasal Spray
PR Newswire - Mon May 12, 8:23AM CDT
Perrigo Company plc (NYSE: PRGO;TASE) announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%). The ANDA involved contributions from both Perrigo and Impax Laboratories, Inc. (Nasdaq: IPXL), who will share certain costs and benefits of this product. Perrigo and Impax continue to be in first to file Hatch Waxman patent litigation with Meda Pharmaceuticals Inc. in the United States District Court for the District of New Jersey. Perrigo has commenced shipment of product to its customers.
Impax Laboratories to Present at Upcoming Investor Conferences
PR Newswire - Mon May 12, 7:30AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will present at two upcoming investor conferences in May.
Insider Trading Alert - IPXL, IVR And VRSK Traded By Insiders
at The Street - Fri May 09, 10:45AM CDT
Stocks with insider trader activity include IPXL, IVR and VRSK
Why Impax Laboratories (IPXL) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:34AM CDT
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on IPXL’s earnings for the coming quarter and year.
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Thu May 08, 7:06AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at Buckingham today. The stock closed yesterday at $26.40 on volume of 777,000 shares, below average daily volume of 868,000. Impax Laboratories has overhead space with shares priced $26.40, or 5.0% below the average consensus analyst price target of $27.78. The stock should find initial support at its 50-day moving average (MA) of $26.00 and further support at its 200-day MA of $23.16.
Depression - Pipeline Review, H1 2014: 55 Companies and 96 Drugs Profiled
M2 - Thu May 08, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2szh97/depression) has announced the addition of the "Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AB Science - Acetylon Pharmaceuticals, Inc. - Ache Laboratorios Farmaceuticos S/A - Acino Pharma AG - Addex Therapeutics - Affectis Pharmaceuticals AG - Allergan, Inc. - Anavex Life Sciences Corp. - Angelini Group - Angita B.V. - Aphios Corporation - AstraZeneca PLC - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - BioCrea GmbH - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Clera Inc. - Concert Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dart NeuroScience LLC - Domain Therapeutics SA - Eisai Co., Ltd. - Eli Lilly and Company - FAES Farma SA - Heptares Therapeutics Ltd. - Hydra Biosciences, Inc. - Impax Laboratories, Inc. - Indus Biotech Private Limited - Intra-Cellular Therapies, Inc. and many more Drug Profiles: - trazodone hydrochloride - quetiapine fumarate ER - Triple Reuptake Inhibitors - verucerfont - masitinib - nefiracetam - epoetin alfa - PH-10-A - CLR-3001 - Neurokinin-1 Receptor Antagonists For Depression - progesterone - SRX-251 - SRX-246 - ITI-007 - RGH-618 - fludrocortisone - BLI-1005 - WF-516 - Projectx-1120 - TS-111 - IPX-237 - SPN-809 - ANAVEX-1-41 - F-98214-TA - Xantol - E-2508 - NNI-351 - INDUS-860 - NW-3509 - SKL-PSY and many more For more information visit http://www.researchandmarkets.com/research/2szh97/depression
Impax Beats Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 1:00PM CDT
Impax Laboratories Inc. (IPXL) reported better-than-expected earnings per share in the first quarter of 2014.
The Shuman Law Firm Investigates Impax Laboratories Inc.
Business Wire - Tue May 06, 11:05AM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Impax Laboratories ("Impax" or the "Company"
(Nasdaq: IPXL). Impax operates as a California-based specialty pharmaceutical company which develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products.
Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:30AM CDT
Shares of Pacira Pharma (PCRX) have been rising since the company reported first quarter results
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:10AM CDT
Shares of Seattle Genetics (SGEN) fell 11.2% in spite of the company???s better-than-expected first quarter results.
Morning Coverage of Equities Reaching New Highs -- Research on AerCap Holdings, Impax Laboratories, FelCor Lodging Trust, and Novartis
PR Newswire - Mon May 05, 7:41AM CDT
The markets on Friday, May 02, 2014 ended on a lower note as the Dow Jones Industrial Average finished the day at 16,512.89, down 0.28%, and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 finished the session 0.13% lower at 1,881.14. The losses were broad based as six out of ten sectors finished negative. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include AerCap Holdings N.V. (NYSE: AER), Impax Laboratories Inc. (NASDAQ: IPXL), FelCor Lodging Trust Inc. (NYSE: FCH) and Novartis AG (NYSE: NVS). Free technical research on AER, IPXL, FCH and NVS can be downloaded upon signing up at:
Shire Beats on Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:05PM CDT
Shire (SHPG) reported first quarter 2014 earnings (excluding special items and amortization) of $2.36 per American Depositary Share (ADS), up from $1.72 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.22.
Novo Nordisk Beats Earnings Ests, Misses Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:10AM CDT
Novo Nordisk reported 1Q14 earnings of 45 cents per ADR, beating the Zacks Consensus Estimate of 44 cents
Teva Misses on Earnings By a Penny, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:10AM CDT
Teva's (TEVA) first quarter earnings and revenues fell short of estimates by a slight margin.
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Impax Laboratories Reports First Quarter 2014 Results
PR Newswire - Thu May 01, 3:01PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported adjusted net income of $16.5 million, or $0.24 per diluted share for the first quarter ended March 31, 2014, compared to adjusted net income of $25.3 million, or $0.37 per diluted share in the prior year period. On a GAAP basis, the Company recorded net income of $6.4 million, or $0.09 per diluted share for the first quarter 2014, compared to net income of $105.4 million, or $1.55 per diluted share in the prior year period.
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
The Law Offices of Nicholas Koluncich III, LLC Announces Investigation of Impax Laboratories (NASDAQ: IPXL) - Seeking Current Shareholders
Business Wire - Tue Apr 29, 9:23AM CDT
The Law Offices of Nicholas Koluncich III, LLC is investigating possible breaches of fiduciary duty by certain officers and directors of Impax Laboratories (NASDAQ IPXL) ("Impax" or "Company" . Current Impax stockholders are therefore encouraged to contact us for a free evaluation of their right to some form of financial recovery. A lawsuit is pending in United States Federal Court alleging that the Company has "Pervasive Manufacturing and QC [Quality Control] Deficiencies" and that Impax CEO Larry Hsu and CFO Arthur Koch made false statements of material fact concerning, in summary terms:
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Insider Trading Alert - IPXL, ITMN And GMCR Traded By Insiders
at The Street - 53 mins ago
Stocks with insider trader activity include IPXL, ITMN and GMCR
Perrigo Company plc Announces FDA Approval Of Generic Version Of Astepro® Nasal Spray
PR Newswire - Mon May 12, 8:23AM CDT
Perrigo Company plc (NYSE: PRGO;TASE) announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%). The ANDA involved contributions from both Perrigo and Impax Laboratories, Inc. (Nasdaq: IPXL), who will share certain costs and benefits of this product. Perrigo and Impax continue to be in first to file Hatch Waxman patent litigation with Meda Pharmaceuticals Inc. in the United States District Court for the District of New Jersey. Perrigo has commenced shipment of product to its customers.
Impax Laboratories to Present at Upcoming Investor Conferences
PR Newswire - Mon May 12, 7:30AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will present at two upcoming investor conferences in May.
Insider Trading Alert - IPXL, IVR And VRSK Traded By Insiders
at The Street - Fri May 09, 10:45AM CDT
Stocks with insider trader activity include IPXL, IVR and VRSK
Why Impax Laboratories (IPXL) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:34AM CDT
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on IPXL’s earnings for the coming quarter and year.
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Thu May 08, 7:06AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at Buckingham today. The stock closed yesterday at $26.40 on volume of 777,000 shares, below average daily volume of 868,000. Impax Laboratories has overhead space with shares priced $26.40, or 5.0% below the average consensus analyst price target of $27.78. The stock should find initial support at its 50-day moving average (MA) of $26.00 and further support at its 200-day MA of $23.16.
Depression - Pipeline Review, H1 2014: 55 Companies and 96 Drugs Profiled
M2 - Thu May 08, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2szh97/depression) has announced the addition of the "Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AB Science - Acetylon Pharmaceuticals, Inc. - Ache Laboratorios Farmaceuticos S/A - Acino Pharma AG - Addex Therapeutics - Affectis Pharmaceuticals AG - Allergan, Inc. - Anavex Life Sciences Corp. - Angelini Group - Angita B.V. - Aphios Corporation - AstraZeneca PLC - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - BioCrea GmbH - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Clera Inc. - Concert Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dart NeuroScience LLC - Domain Therapeutics SA - Eisai Co., Ltd. - Eli Lilly and Company - FAES Farma SA - Heptares Therapeutics Ltd. - Hydra Biosciences, Inc. - Impax Laboratories, Inc. - Indus Biotech Private Limited - Intra-Cellular Therapies, Inc. and many more Drug Profiles: - trazodone hydrochloride - quetiapine fumarate ER - Triple Reuptake Inhibitors - verucerfont - masitinib - nefiracetam - epoetin alfa - PH-10-A - CLR-3001 - Neurokinin-1 Receptor Antagonists For Depression - progesterone - SRX-251 - SRX-246 - ITI-007 - RGH-618 - fludrocortisone - BLI-1005 - WF-516 - Projectx-1120 - TS-111 - IPX-237 - SPN-809 - ANAVEX-1-41 - F-98214-TA - Xantol - E-2508 - NNI-351 - INDUS-860 - NW-3509 - SKL-PSY and many more For more information visit http://www.researchandmarkets.com/research/2szh97/depression
Impax Beats Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 1:00PM CDT
Impax Laboratories Inc. (IPXL) reported better-than-expected earnings per share in the first quarter of 2014.
The Shuman Law Firm Investigates Impax Laboratories Inc.
Business Wire - Tue May 06, 11:05AM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Impax Laboratories ("Impax" or the "Company"
(Nasdaq: IPXL). Impax operates as a California-based specialty pharmaceutical company which develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:30AM CDT
Shares of Pacira Pharma (PCRX) have been rising since the company reported first quarter results
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:10AM CDT
Shares of Seattle Genetics (SGEN) fell 11.2% in spite of the company???s better-than-expected first quarter results.
Morning Coverage of Equities Reaching New Highs -- Research on AerCap Holdings, Impax Laboratories, FelCor Lodging Trust, and Novartis
PR Newswire - Mon May 05, 7:41AM CDT
The markets on Friday, May 02, 2014 ended on a lower note as the Dow Jones Industrial Average finished the day at 16,512.89, down 0.28%, and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 finished the session 0.13% lower at 1,881.14. The losses were broad based as six out of ten sectors finished negative. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include AerCap Holdings N.V. (NYSE: AER), Impax Laboratories Inc. (NASDAQ: IPXL), FelCor Lodging Trust Inc. (NYSE: FCH) and Novartis AG (NYSE: NVS). Free technical research on AER, IPXL, FCH and NVS can be downloaded upon signing up at:
Shire Beats on Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:05PM CDT
Shire (SHPG) reported first quarter 2014 earnings (excluding special items and amortization) of $2.36 per American Depositary Share (ADS), up from $1.72 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.22.
Novo Nordisk Beats Earnings Ests, Misses Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 10:10AM CDT
Novo Nordisk reported 1Q14 earnings of 45 cents per ADR, beating the Zacks Consensus Estimate of 44 cents
Teva Misses on Earnings By a Penny, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:10AM CDT
Teva's (TEVA) first quarter earnings and revenues fell short of estimates by a slight margin.
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Impax Laboratories Reports First Quarter 2014 Results
PR Newswire - Thu May 01, 3:01PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported adjusted net income of $16.5 million, or $0.24 per diluted share for the first quarter ended March 31, 2014, compared to adjusted net income of $25.3 million, or $0.37 per diluted share in the prior year period. On a GAAP basis, the Company recorded net income of $6.4 million, or $0.09 per diluted share for the first quarter 2014, compared to net income of $105.4 million, or $1.55 per diluted share in the prior year period.
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
The Law Offices of Nicholas Koluncich III, LLC Announces Investigation of Impax Laboratories (NASDAQ: IPXL) - Seeking Current Shareholders
Business Wire - Tue Apr 29, 9:23AM CDT
The Law Offices of Nicholas Koluncich III, LLC is investigating possible breaches of fiduciary duty by certain officers and directors of Impax Laboratories (NASDAQ IPXL) ("Impax" or "Company"
. Current Impax stockholders are therefore encouraged to contact us for a free evaluation of their right to some form of financial recovery. A lawsuit is pending in United States Federal Court alleging that the Company has "Pervasive Manufacturing and QC [Quality Control] Deficiencies" and that Impax CEO Larry Hsu and CFO Arthur Koch made false statements of material fact concerning, in summary terms: Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
